Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden have?
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden has 3,158 citations in the OpenAlex counts ScholarIQ stores.
When was Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden published?
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden has 2018 year in the ScholarIQ index.
What is the open-access status of Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden?
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden has bronze oa status in the ScholarIQ index.
What is the DOI of Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden?
The DOI for Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden is on the source record.
What is the PMID of Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden?
The PMID for Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden is on the source record.
What is the OpenAlex record for Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden?
The OpenAlex for Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden is on the source record.